Health Economics›Non-small cell lung cancer›Advanced or metastatic disease first-line

Advanced or metastatic disease first-line

Non-small cell lung cancer · 59 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 14 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP) and Ipilimumab Variant #01	—	R 788 598	21d	—	~13.4 mo	—	—	1
Carboplatin and nab-Paclitaxel (CnP), Durvalumab, Tremelimumab Variant #01 Partial	—	R 310 137	28d	6.2 mo	14.0 mo	7	R 2 170 960 PFS proxy	3
Carboplatin and nab-Paclitaxel (CnP) and Durvalumab Variant #01	—	R 310 137	28d	5.5 mo	13.3 mo	6	R 1 860 823 PFS proxy	3
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	8.4 mo	22.1 mo	19	R 5 452 150 PFS proxy	9
Durvalumab and Tremelimumab Variant #01 Partial	—	R 131 701	28d	—	11.7 mo	—	—	1
Cisplatin and Gemcitabine (GC) and Cetuximab Variant #01	—	R 77 960	21d	—	—	—	—	—
Cisplatin and Vinorelbine (CVb) and Cetuximab Variant #01	—	R 74 918	21d	—	11.3 mo	—	—	1
Dabrafenib and Trametinib Variant #01	BRAF	R 52 791	28d	~10.7 mo	—	~12	~R 633 492 PFS proxy · indirect	6
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #12	—	R 45 174	21d	—	10.9 mo	—	—	1
Carboplatin and nab-Paclitaxel (CnP) Variant #01	—	R 38 912	21d	—	—	—	—	2
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	20.2 mo	—	—	2
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	6.0 mo	10.4 mo	4	R 61 352 PFS proxy	14
GIP Variant #01	—	R 14 703	21d	—	—	—	—	—
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	—	6.2 mo	—	—	4
VeIP Variant #01	—	R 12 305	21d	—	—	—	—	—
Ifosfamide and Gemcitabine Variant #01	—	R 9 944	28d	—	—	—	—	—
Ifosfamide monotherapy N/A - secondary systemic drug	—	R 9 835	28d	~4.0 mo	~8.4 mo	~5	~R 49 173 PFS proxy · indirect	2
CCI Variant #01	—	R 9 427	28d	—	—	—	—	—
MIC Variant #02	—	R 7 668	21d	—	7.6 mo	—	—	1
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	5.3 mo	10.3 mo	8	R 40 246 PFS proxy	32
Docetaxel and Gemcitabine Variant #01	—	R 4 912	21d	—	9.4 mo	—	—	—
Cisplatin and Etoposide (EP) Variant #01	—	R 4 264	42d	—	7.6 mo	—	—	—
Cisplatin and Vinorelbine (CVb) Variant #11	—	R 4 117	42d	—	9.8 mo	—	—	6
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 3 663	21d	6.0 mo	10.0 mo	9	R 32 967 PFS proxy	7
Gemcitabine and Vinorelbine Variant #01	—	R 3 329	21d	—	6.7 mo	—	—	2
Carboplatin and Docetaxel (DCb) Variant #01	—	R 3 300	21d	4.2 mo	8.2 mo	7	R 23 101 PFS proxy	2
MVP (Vinblastine) Variant #01	—	R 2 750	28d	—	—	—	—	—
Carboplatin and Paclitaxel (CP) and Cemiplimab Variant #01 Partial	—	R 2 413	21d	—	21.5 mo	—	—	2
MVP (Vindesine) Variant #01 Partial	—	R 2 349	28d	—	—	—	—	—
Carboplatin and Etoposide (CE) Variant #10	—	R 2 265	21d	~4.6 mo	~10.6 mo	~7	~R 15 853 PFS proxy · indirect	17
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	—	6.8 mo	—	—	2
Docetaxel and Vinorelbine Variant #01	—	R 2 093	14d	—	—	—	—	—
Cisplatin and Vinblastine Variant #03	—	R 1 973	28d	—	13.7 mo	—	—	—
Cisplatin and Vindesine Variant #05 Partial	—	R 1 800	63d	—	—	—	—	1
Cisplatin and Paclitaxel (TP) and Cemiplimab Variant #01 Partial	—	R 1 762	21d	—	21.5 mo	—	—	2
Carboplatin and Vinorelbine Variant #01	—	R 1 609	21d	—	6.7 mo	—	—	1
FULV Variant #01	—	R 1 466	35d	~5.6 mo	~13.1 mo	~5	~R 7 330 PFS proxy · indirect	15
Cisplatin and Pemetrexed Variant #01	—	R 1 088	21d	8.6 mo	13.1 mo	13	R 14 139 PFS proxy	5
Carboplatin and S-1 Variant #01 Partial	—	R 1 026	21d	—	15.2 mo	—	—	1
Carboplatin and Cisplatin Variant #01	—	R 906	28d	—	—	—	—	—
Cisplatin and Irinotecan (IC) N/A - secondary systemic drug	—	R 743	42d	—	13.9 mo	—	—	4
Cisplatin and Paclitaxel (TP) Variant #01	—	R 716	10d	5.3 mo	9.5 mo	17	R 12 175 PFS proxy	4
CISCA Variant #02	—	R 678	21d	—	—	—	—	—
Cisplatin monotherapy Variant #16	—	R 650	28d	—	8.6 mo	—	—	1
Vinorelbine monotherapy Variant #01	—	R 583	21d	—	6.2 mo	—	—	3
CAMP Variant #01 Partial	—	R 527	28d	—	—	—	—	—
MACC Variant #01 Partial	—	R 480	21d	—	—	—	—	—
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug	—	R 449	21d	—	13.0 mo	—	—	2
Cisplatin and S-1 Variant #01 Partial	—	R 375	28d	—	16.1 mo	—	—	1
Gemcitabine and Paclitaxel N/A - secondary systemic drug	—	R 263	28d	—	9.8 mo	—	—	1
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	—	8.4 mo	—	—	2
Carboplatin and Pemetrexed N/A - secondary systemic drug	—	R 52	21d	8.6 mo	13.3 mo	13	R 677 PFS proxy	6
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	—	10.6 mo	—	—	1
Carboplatin and Gemcitabine (GCb) and Paclitaxel N/A - secondary systemic drug	—	R 36	21d	—	10.8 mo	—	—	1
Best supportive care Partial	—	—	—	—	4.8 mo	—	—	1
Nivolumab monotherapy Variant #01 Partial	—	—	14d	4.2 mo	—	10	—	1
Vindesine monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Cemiplimab monotherapy Variant #01 Partial	—	—	21d	10.3 mo	26.1 mo	15	—	5
Placebo Partial	—	—	—	—	3.6 mo	—	—	1

59 of 59 regimens shown